Eli Lilly beats on 1st-qtr earnings but sales hit by pricing pressures

30 April 2019

US pharma major Eli Lilly (NYSE: LLY) posted financials this morning, showing that, for the first quarter of 2019, worldwide revenue was $5.092 billion, an increase of 3% compared with the first quarter of 2018, but missing the consensus forecast of $5.2 billion.

The increase in revenue was driven by a 7% increase due to volume, partially offset by a 3% decrease due to lower realized prices, and a 2% decrease due to the unfavorable impact of foreign exchange rates.

First-quarter 2019 earnings per share (EPS) grew to $4.31 on a reported basis, or $1.33 on a non-generally accepted accounting principles (GAAP) basis. Lilly beat earnings per share expectations in the first quarter, reporting non-GAAP EPS of $1.33, higher than the average analyst estimate for $1.32 and up 2% year-on-year. Net income was $4.2 billion due to the spin off of Elanco.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK